New CDMO, backed by private equity player, to manufacture biologics

New CDMO TriPharm Services has picked Morrisville, North Carolina, to build its 32,000-square-foot facility for manufacturing biologics and other sterile injectables. (TriPharm Services)

Private equity player Ampersand Capital Partners, which this year sold Brammer Bio for $1.7 billion, is investing in another U.S. CDMO, this one targeted at sterile injectables.

TriPharm Services Wednesday announced it would set up a 32,000-square-foot facility in Morrisville, North Carolina, with four isolator filling suites and eight clean rooms to manufacture biologics. It said it expects the site to be fully operational by the second quarter of 2020. Terms of the investments were not released.

Ampersand Capital Partners has been busy this year. In March, it sold Brammer Bio for $1.7 billion to Thermo Fisher Scientific, giving Thermo Fisher entry into the growing gene and cell therapy market. Cambridge, Massachusetts-based Brammer has expertise in viral vector manufacturing. Thermo Fisher has been expanding its contract manufacturing operations since acquiring Patheon in 2017.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Just weeks after it sold Brammer, Ampersand Capital bought Germany-based Vibalogics. The 50-person CDMO specializes in viruses and has a 27,000-square-foot facility in Cuxhaven, Germany. Terms of the deal were not disclosed.

Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.